Categories Earnings, Health Care

Cancer drugs boost AstraZeneca results in Q1

Riding on the strong demand for its cancer drugs, AstraZeneca Plc (NYSE: AZN) on Friday reported its third consecutive quarter of top line growth. Product sales for the quarter jumped 14% to $5.46 billion, without taking into account the impact of currency fluctuations.

Product sales were primarily boosted by the oncology segment, where sales improved 59%, with particular strength in emerging markets including China.

AstraZeneca Product Sales Mix

Total revenue grew 11% to $5.49 billion, surpassing analysts’ projection of $5.27 billion. Core EPS doubled to 89 cents per share, beating the consensus estimate by 46 cents.

Lung Cancer drug Tagrisso was the best selling product during the quarter. Sale of this drug almost doubled to $630 million and accounted for 12% of its total product sales.

AstraZeneca product sales growth by segment

CEO Pascal Soriot said, “Our 14% Product Sales growth in the quarter reflected the success of our new medicines and Emerging Markets. In Oncology, Tagrisso, Imfinzi, and Lynparza continued to do well and, in BioPharma, Farxiga, Brilinta, and Fasenra also grew strongly.”


“The recently-announced collaboration with Daiichi Sankyo also broadened an exciting Oncology portfolio with a potentially-transformative cancer treatment that could benefit patients around the world,” he added.


The British-Swedish biopharmaceutical company revised its guidance following the solid results. The company now expects full-year 2019 product sales in a high single-digit percentage increase. Core EPS is projected in the range of $3.50 to $3.70.

AZN shares were down 1.4% during pre-market trading on Friday. The stock has gained 2.6% in the year-to-date period.

Also Read:  Moderna, Inc. (MRNA) Q2 2020 Earnings Conference Call Transcript


Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

3D Systems Corp. (DDD) Q2 2020 Earnings Call Transcript

3D Systems Corp. (NYSE: DDD) Q2 2020 earnings call dated Aug. 05, 2020 Corporate Participants: Jessica Stansell -- Investor Relations Jeffrey A. Graves -- Chief Executive Officer And President Wayne Pensky -- Interim Chief Financial Officer Analysts:

Yelp (YELP): Revenue recovery depends significantly on COVID-19 environment

Shares of Yelp (NYSE: YELP) were down over 15% on Friday, a day after the company reported a decline in revenue along with a net loss for the second quarter

US economy adds 1.8 million jobs in July; unemployment rate drops to 10.2%

The US economy added 1.8 million jobs in July, marking the third consecutive month of employment growth as the country recovers from the coronavirus pandemic that has caused widespread disruption.